CareDx Form 4: Michael Goldberg Adds Quarterly Stock Grant
Rhea-AI Filing Summary
On July 8, 2025, CareDx, Inc. (CDNA) director Michael Goldberg filed a Form 4 reporting receipt of 1,218 shares of common stock at a grant price of $0 under the company’s Outside Director Compensation Policy. The automatic equity award, issued in lieu of quarterly cash fees, raises his direct ownership to 154,216 shares. No open-market purchases, sales or derivative transactions were disclosed, indicating the filing is a routine governance matter rather than a signal of insider sentiment.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine director stock grant; neutral signal for CDNA.
The 1,218-share award to Director Michael Goldberg represents about 0.8% of his 154k-share stake and less than 0.003% of CareDx’s shares outstanding. Because it is an automatic quarterly grant issued at $0, the transaction does not reflect proactive insider buying or selling pressure. As such, the Form 4 is unlikely to affect valuation, liquidity, or market sentiment; it mainly satisfies Section 16 reporting requirements.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 1,218 | $0.00 | $0.00 |
Footnotes (1)
- F1. Represents an automatic quarterly grant of common stock to the Reporting Person in lieu of cash for non-employee director compensation pursuant to the issuer's Outside Director Compensation Policy.
FAQ
What insider transaction was reported for CDNA on July 8, 2025?
Was the equity grant executed under a Rule 10b5-1 trading plan?
Did the Form 4 disclose any sales or derivative transactions?
AI-generated analysis. How Rhea-AI works. Not financial advice.